Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. (2020)

• Record Type: Journal Article
• Authors: Melody, Megan; Butts, Emily; Menke, David; Landolfo, Kevin; Oken, Keith; Sher, Taimur; Khurana, Sharad
• Is Part Of: Leukemia research reports. Volume 14(2020)
• Publication Date: 2020
• Subjects: Chronic myelomonocytic leukemia -- Tocilizumab -- Leukemoid reaction -- Systemic inflammatory response; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2020.100228
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.